Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H23N7O6.H2O4S |
| Molecular Weight | 555.518 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.[H][C@@]12CN(CN1C3=C(NC2)NC(N)=NC3=O)C4=CC=C(C=C4)C(=O)N[C@@H](CCC(O)=O)C(O)=O
InChI
InChIKey=GKJSPWCDMPVQHB-KZCZEQIWSA-N
InChI=1S/C20H23N7O6.H2O4S/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29;1-5(2,3)4/h1-4,12-13H,5-9H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31);(H2,1,2,3,4)/t12-,13+;/m1./s1
| Molecular Formula | H2O4S |
| Molecular Weight | 98.078 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C20H23N7O6 |
| Molecular Weight | 457.4399 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
METHYLENETETRAHYDROFOLIC ACID, L-(+), an endogenous biomodulator that was developed under the brand name modufolin or arfolitixorin by the Isofol Medical. Arfolitixorin is developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. This drug is currently being studied in a global phase 3 clinical trial. Besides, the drug successfully completed phase II as rescue therapy for osteosarcoma. 21 May 2019 Isofol Medical has received clinical patent protection for the arfolitixorinin USA. It relates to a method of increasing blood concentration of deoxyuridine, a blood biomarker for inhibition of tumor growth in human cancer treatment.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Molecular biology of 5,10-methylenetetrahydrofolate reductase. | 2000 Jan-Feb |
|
| Formaldehyde-detoxifying role of the tetrahydromethanopterin-linked pathway in Methylobacterium extorquens AM1. | 2003 Dec |
|
| Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer. | 2015 Oct |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 14:20:35 UTC 2023
by
admin
on
Sat Dec 16 14:20:35 UTC 2023
|
| Record UNII |
PO4XPF4TIX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
137331911
Created by
admin on Sat Dec 16 14:20:35 UTC 2023 , Edited by admin on Sat Dec 16 14:20:35 UTC 2023
|
PRIMARY | |||
|
PO4XPF4TIX
Created by
admin on Sat Dec 16 14:20:35 UTC 2023 , Edited by admin on Sat Dec 16 14:20:35 UTC 2023
|
PRIMARY | |||
|
149930-93-8
Created by
admin on Sat Dec 16 14:20:35 UTC 2023 , Edited by admin on Sat Dec 16 14:20:35 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |